新型生物药物深入治疗银屑病。 - Suppr

Suppr

超能文献

New biologic drugs get under the skin of psoriasis.

作者信息

Williams Sarah C P

出版信息

Nat Med. 2012 May 4;18(5):638. doi: 10.1038/nm0512-638.

DOI:10.1038/nm0512-638

PMID:22561807

Abstract

摘要

相似文献

New biologic drugs get under the skin of psoriasis.

Nat Med. 2012 May 4;18(5):638. doi: 10.1038/nm0512-638.

Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis.

Eur J Dermatol. 2014 Jan-Feb;24(1):133-5. doi: 10.1684/ejd.2014.2269.

Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis.

N Engl J Med. 2012 Jul 19;367(3):274; author reply 275. doi: 10.1056/NEJMc1205835.

Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis.

N Engl J Med. 2012 Jul 19;367(3):274-5; author reply 275. doi: 10.1056/NEJMc1205835.

To be 17 again--anti-interleukin-17 treatment for psoriasis.

N Engl J Med. 2012 Mar 29;366(13):1251-2. doi: 10.1056/NEJMe1201071.

IL-17 Blockade in Psoriasis.

Cell. 2016 Dec 15;167(7):1669. doi: 10.1016/j.cell.2016.11.044.

Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.

Hum Vaccin Immunother. 2017 Oct 3;13(10):2247-2259. doi: 10.1080/21645515.2017.1356498.

IL-17 inhibitors for psoriasis.

Semin Cutan Med Surg. 2018 Sep;37(3):148-157. doi: 10.12788/j.sder.2018.051.

The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.

J Cutan Med Surg. 2016 Nov;20(6):509-516. doi: 10.1177/1203475416651605. Epub 2016 May 20.

Erythrodermic psoriasis improved by panitumumab, but not bevacizumab.

Acta Derm Venereol. 2012 Jul;92(4):360-1. doi: 10.2340/00015555-1348.

引用本文的文献

Therapeutic Effects of Synthetic Antimicrobial Peptides, TRAIL and NRP1 Blocking Peptides in Psoriatic Keratinocytes.

Chonnam Med J. 2019 May;55(2):75-85. doi: 10.4068/cmj.2019.55.2.75. Epub 2019 May 23.

Systematic screening and identification of novel psoriasis‑specific genes from the transcriptome of psoriasis‑like keratinocytes.

Mol Med Rep. 2019 Mar;19(3):1529-1542. doi: 10.3892/mmr.2018.9782. Epub 2018 Dec 20.

Genome wide transcriptome analysis of dendritic cells identifies genes with altered expression in psoriasis.

PLoS One. 2013 Sep 9;8(9):e73435. doi: 10.1371/journal.pone.0073435. eCollection 2013.

IL-17 in the rheumatologist's line of sight.

Biomed Res Int. 2013;2013:295132. doi: 10.1155/2013/295132. Epub 2013 Jul 25.

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

Br J Dermatol. 2013 Jul;169(1):137-45. doi: 10.1111/bjd.12266.

本文引用的文献

Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.

N Engl J Med. 2012 Mar 29;366(13):1190-9. doi: 10.1056/NEJMoa1109997.

Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

N Engl J Med. 2012 Mar 29;366(13):1181-9. doi: 10.1056/NEJMoa1109017.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

New biologic drugs get under the skin of psoriasis.

Nat Med. 2012 May 4;18(5):638. doi: 10.1038/nm0512-638.

Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis.

Eur J Dermatol. 2014 Jan-Feb;24(1):133-5. doi: 10.1684/ejd.2014.2269.

Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis.

N Engl J Med. 2012 Jul 19;367(3):274; author reply 275. doi: 10.1056/NEJMc1205835.

Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis.

N Engl J Med. 2012 Jul 19;367(3):274-5; author reply 275. doi: 10.1056/NEJMc1205835.

To be 17 again--anti-interleukin-17 treatment for psoriasis.

N Engl J Med. 2012 Mar 29;366(13):1251-2. doi: 10.1056/NEJMe1201071.

IL-17 Blockade in Psoriasis.

Cell. 2016 Dec 15;167(7):1669. doi: 10.1016/j.cell.2016.11.044.

Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.

Hum Vaccin Immunother. 2017 Oct 3;13(10):2247-2259. doi: 10.1080/21645515.2017.1356498.

IL-17 inhibitors for psoriasis.

Semin Cutan Med Surg. 2018 Sep;37(3):148-157. doi: 10.12788/j.sder.2018.051.

The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.

J Cutan Med Surg. 2016 Nov;20(6):509-516. doi: 10.1177/1203475416651605. Epub 2016 May 20.

Erythrodermic psoriasis improved by panitumumab, but not bevacizumab.

Acta Derm Venereol. 2012 Jul;92(4):360-1. doi: 10.2340/00015555-1348.

引用本文的文献

Therapeutic Effects of Synthetic Antimicrobial Peptides, TRAIL and NRP1 Blocking Peptides in Psoriatic Keratinocytes.

Chonnam Med J. 2019 May;55(2):75-85. doi: 10.4068/cmj.2019.55.2.75. Epub 2019 May 23.

Systematic screening and identification of novel psoriasis‑specific genes from the transcriptome of psoriasis‑like keratinocytes.

Mol Med Rep. 2019 Mar;19(3):1529-1542. doi: 10.3892/mmr.2018.9782. Epub 2018 Dec 20.

Genome wide transcriptome analysis of dendritic cells identifies genes with altered expression in psoriasis.

PLoS One. 2013 Sep 9;8(9):e73435. doi: 10.1371/journal.pone.0073435. eCollection 2013.

IL-17 in the rheumatologist's line of sight.

Biomed Res Int. 2013;2013:295132. doi: 10.1155/2013/295132. Epub 2013 Jul 25.

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

Br J Dermatol. 2013 Jul;169(1):137-45. doi: 10.1111/bjd.12266.

本文引用的文献

Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.

N Engl J Med. 2012 Mar 29;366(13):1190-9. doi: 10.1056/NEJMoa1109997.

Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

N Engl J Med. 2012 Mar 29;366(13):1181-9. doi: 10.1056/NEJMoa1109017.